Trends in molecular medicine最新文献

筛选
英文 中文
Beyond the skin: how skin-derived signals shape systemic immunity. 超越皮肤:皮肤来源的信号如何塑造全身免疫。
IF 18.1 1区 医学
Trends in molecular medicine Pub Date : 2026-11-06 DOI: 10.1016/j.molmed.2026.10.002
Qiaolin Wang, Yutong Wu, Limin Liu, Ming Zhao
{"title":"Beyond the skin: how skin-derived signals shape systemic immunity.","authors":"Qiaolin Wang, Yutong Wu, Limin Liu, Ming Zhao","doi":"10.1016/j.molmed.2026.10.002","DOIUrl":"https://doi.org/10.1016/j.molmed.2026.10.002","url":null,"abstract":"<p><p>The skin has emerged as an active regulator of systemic immunity, extending its influence beyond the local tissue microenvironment. In this Forum, we discuss how skin-derived metabolic signals, inflammatory mediators, and migratory immune cells coordinate systemic immune responses and highlight their translational potential for vaccine development and skin-associated systemic diseases.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":18.1,"publicationDate":"2026-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149358086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesoscale tissue states in fibrosis: from pathway targeting to state-directed therapy. 纤维化的中尺度组织状态:从途径靶向到状态导向治疗。
IF 18.1 1区 医学
Trends in molecular medicine Pub Date : 2026-11-05 DOI: 10.1016/j.molmed.2026.10.001
Mark G Jones, Danny Jonigk, Joseph Jacob
{"title":"Mesoscale tissue states in fibrosis: from pathway targeting to state-directed therapy.","authors":"Mark G Jones, Danny Jonigk, Joseph Jacob","doi":"10.1016/j.molmed.2026.10.001","DOIUrl":"https://doi.org/10.1016/j.molmed.2026.10.001","url":null,"abstract":"<p><p>Fibrosis is a major cause of organ dysfunction, yet current antifibrotic therapies slow functional decline without durably arresting disease progression or restoring tissue architecture. This therapeutic ceiling suggests that determinants of progressive fibrosis extend beyond individual molecular pathways. In this review, we propose that progressive fibrosis represents a pathological state transition in which a plastic tissue microenvironment becomes a self-sustaining mesoscale fibrotic tissue module. Within this state, cellular plasticity is retained but misdirected towards maladaptive repair. Tissue behaviour emerges from spatial organisation and coupled multicellular dynamics that cannot be predicted from individual signalling pathways alone. This framework explains why pathway-centric therapies attenuate fibrogenic activity without reversing the underlying tissue state. We propose a state-directed paradigm in which pathological tissue modules must be unlocked to restore tissue plasticity and re-establish tissue homoeostasis.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":18.1,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149343616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends at 50: a mission that matters. 50岁的趋势:重要的使命。
IF 18.1 1区 医学
Trends in molecular medicine Pub Date : 2026-11-04 DOI: 10.1016/j.molmed.2026.10.003
{"title":"Trends at 50: a mission that matters.","authors":"","doi":"10.1016/j.molmed.2026.10.003","DOIUrl":"https://doi.org/10.1016/j.molmed.2026.10.003","url":null,"abstract":"","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":""},"PeriodicalIF":18.1,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the hyaluronic acid-CD44 axis in hepatocellular carcinoma. 靶向肝细胞癌透明质酸- cd44轴。
IF 18.1 1区 医学
Trends in molecular medicine Pub Date : 2026-11-01 Epub Date: 2026-04-11 DOI: 10.1016/j.molmed.2026.03.008
Georgia Zancotti, Gisela Weiz, Cyrollah Disoma, Claudio Tiribelli, Caecilia Sukowati
{"title":"Targeting the hyaluronic acid-CD44 axis in hepatocellular carcinoma.","authors":"Georgia Zancotti, Gisela Weiz, Cyrollah Disoma, Claudio Tiribelli, Caecilia Sukowati","doi":"10.1016/j.molmed.2026.03.008","DOIUrl":"10.1016/j.molmed.2026.03.008","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) remains a major global health challenge, with rising incidence, frequent development of drug resistance, and limited long-term survival despite advances in systemic therapies. Within the tumor microenvironment, the interaction between hyaluronic acid (HA) and cluster of differentiation 44 (CD44) is linked to tumor progression and therapeutic failure. Accordingly, targeting the HA-CD44 signaling axis represents a promising strategy to overcome resistance. This review highlights potential approaches, including inhibition of HA synthesis, enzymatic HA degradation, CD44 blockade, and HA-based nanocarriers for selective drug delivery, alone or combined with existing therapies. Leveraging HA-CD44 biology may help refine profiling and support the development of more personalized treatments, ultimately enhancing outcomes for HCC patients.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"1114-1126"},"PeriodicalIF":18.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Muscle-to-CNS signaling in physiological homeostasis, aging, and disease. 生理稳态、衰老和疾病中的肌肉到中枢神经系统信号。
IF 18.1 1区 医学
Trends in molecular medicine Pub Date : 2026-11-01 Epub Date: 2026-03-31 DOI: 10.1016/j.molmed.2026.03.006
Chia-Lung Chuang, Mamta Rai, Fabio Demontis
{"title":"Muscle-to-CNS signaling in physiological homeostasis, aging, and disease.","authors":"Chia-Lung Chuang, Mamta Rai, Fabio Demontis","doi":"10.1016/j.molmed.2026.03.006","DOIUrl":"10.1016/j.molmed.2026.03.006","url":null,"abstract":"<p><p>The central nervous system (CNS) orchestrates homeostatic responses and organismal behaviors by integrating cues from the whole body. Like other peripheral tissues, skeletal muscle can signal to the brain, and this occurs via muscle-secreted signaling factors (myokines/myometabolites). In this review article, we examine exercise-induced myokines and myometabolites that improve cognitive capacity and impede neurodegeneration and, conversely, detrimental myokines secreted by diseased muscles that negatively impact brain function. Cellular processes modulated by myokines in the CNS include proteostasis, angiogenesis, neurogenesis, synaptic plasticity, cell senescence, and neuroinflammation, resulting in the modulation of diverse behaviors, such as motor control, memory, foraging, and sleep. Collectively, muscle-to-brain signaling emerges as an important influencer of CNS function and aging, with the prospect of utilizing myokine-/myometabolite-based therapies for treating neurodegeneration.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"1069-1084"},"PeriodicalIF":18.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147594927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Formicitoxins: membrane-targeting antifungal peptides from carpenter ant venoms. Formicitoxins:来自木蚁毒液的膜靶向抗真菌肽。
IF 18.1 1区 医学
Trends in molecular medicine Pub Date : 2026-11-01 Epub Date: 2026-08-14 DOI: 10.1016/j.molmed.2026.07.010
Wei Zhang, Melina Sarabandi, Vinit Kumar
{"title":"Formicitoxins: membrane-targeting antifungal peptides from carpenter ant venoms.","authors":"Wei Zhang, Melina Sarabandi, Vinit Kumar","doi":"10.1016/j.molmed.2026.07.010","DOIUrl":"10.1016/j.molmed.2026.07.010","url":null,"abstract":"<p><p>Fungal infections cause millions of deaths, yet clinical antifungals span only three drug classes. Koch et al. discover formicitoxins-35 venom peptides from carpenter ants-which are the first from any formicine species. Two outperform voriconazole in vitro and delay infection in vivo. Formicitoxins disrupt fungal membranes independently of existing drug targets.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"1050-1052"},"PeriodicalIF":18.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148765300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ubiquitin-specific peptidase 22 targeting: Tumor cell erasure, immune engine unleashed. 靶向泛素特异性肽酶22:肿瘤细胞清除,免疫引擎释放。
IF 18.1 1区 医学
Trends in molecular medicine Pub Date : 2026-11-01 Epub Date: 2026-07-16 DOI: 10.1016/j.molmed.2026.06.012
Deyu Fang
{"title":"Ubiquitin-specific peptidase 22 targeting: Tumor cell erasure, immune engine unleashed.","authors":"Deyu Fang","doi":"10.1016/j.molmed.2026.06.012","DOIUrl":"10.1016/j.molmed.2026.06.012","url":null,"abstract":"<p><p>Deubiquitinases regulate key oncogenic and immune pathways but have proven challenging to exploit therapeutically. Among them, ubiquitin-specific protease 22 (USP22) has emerged as a molecule of interest due to its involvement in both tumor-intrinsic programs and tumor-immune interactions. In this review, we synthesize current evidence describing how USP22 modulates oncogenic transcriptional states and immune evasion. Tumor-intrinsically, USP22 has been implicated in stabilizing select oncogenic factors and shaping chromatin accessibility in ways that can reinforce proliferation, survival, stem-like properties, and metastatic potential. In parallel, USP22 influences antitumor immunity by modulating MHC-I-mediated antigen presentation, immune checkpoint expression, and the fitness of intratumoral regulatory T cells. We discuss emerging pharmacological approaches to target USP22, the limitations of current inhibitor strategies, and the importance of distinguishing direct enzymatic functions from indirect transcriptional consequences. Together, these insights suggest that USP22 inhibition may offer a therapeutic strategy with dual effects on tumor biology and antitumor immunity.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"1085-1099"},"PeriodicalIF":18.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148472641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondrial dysfunction in cerebrovascular diseases. 脑血管疾病的线粒体功能障碍。
IF 18.1 1区 医学
Trends in molecular medicine Pub Date : 2026-11-01 Epub Date: 2026-04-30 DOI: 10.1016/j.molmed.2026.04.002
Fabio Marcheggiani, Ilaria Nunzi, Loredana Rao, Nada Dhaouadi, Salvatore Nesci, Paolo Pinton, Saverio Marchi
{"title":"Mitochondrial dysfunction in cerebrovascular diseases.","authors":"Fabio Marcheggiani, Ilaria Nunzi, Loredana Rao, Nada Dhaouadi, Salvatore Nesci, Paolo Pinton, Saverio Marchi","doi":"10.1016/j.molmed.2026.04.002","DOIUrl":"10.1016/j.molmed.2026.04.002","url":null,"abstract":"<p><p>Mitochondria are central regulators of cerebrovascular health through their control of energy metabolism, Ca<sup>2+</sup> homeostasis, and redox signaling, and their dysfunction represents a convergent pathogenic mechanism across cerebrovascular diseases. In ischemic stroke, mitochondrial failure exacerbates neuronal injury via permeability transition pore opening, oxidative stress, and bioenergetic collapse, while altered mitochondrial dynamics and the release of mitochondrial damage-associated molecular patterns amplify neuroinflammation during reperfusion. Beyond stroke, mitochondrial dysfunction contributes to intracranial aneurysms, atherosclerotic stenosis, and vascular malformations, where oxidative stress, mitochondrial DNA instability, and cell type-specific metabolic reprogramming drive vascular remodeling and lesion progression. In this review, we integrate recent evidence highlighting context- and stage-dependent roles of mitochondria in cerebrovascular pathology and discuss implications for biomarker discovery, therapeutic targeting, and translational strategies.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"1127-1143"},"PeriodicalIF":18.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147821094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is endometriosis a progressive disease? 子宫内膜异位症是一种进行性疾病吗?
IF 18.1 1区 医学
Trends in molecular medicine Pub Date : 2026-11-01 Epub Date: 2026-03-20 DOI: 10.1016/j.molmed.2026.02.011
Sun-Wei Guo, Michel Canis, Paolo P Vercellini
{"title":"Is endometriosis a progressive disease?","authors":"Sun-Wei Guo, Michel Canis, Paolo P Vercellini","doi":"10.1016/j.molmed.2026.02.011","DOIUrl":"10.1016/j.molmed.2026.02.011","url":null,"abstract":"<p><p>Whether endometriosis is a progressive disease remains debated. Central to this debate is understanding the natural history of endometriotic lesions, which are essentially wounds undergoing repeated tissue injury and repair. Viewing the disease through this lens, we reassess the literature on the progression, or absence thereof, of endometriosis and offer our perspective on this debate by delineating the aggravating and mitigating factors that influence lesional progression. We propose that the degree of lesional fibrosis, measurable via elastography as lesional stiffness, represents a promising marker for progression, as it correlates with aberrant histology, molecular alterations, symptom severity, clinical prognosis, and lesional mechanobiology. Lesional stiffness could aid in diagnosis, guide treatment choice, and predict outcomes, providing a valuable tool for managing endometriosis.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"1053-1068"},"PeriodicalIF":18.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147494476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting the NAD+-PARP1-XRCC1 axis in ALS. 在ALS中靶向NAD+-PARP1-XRCC1轴。
IF 18.1 1区 医学
Trends in molecular medicine Pub Date : 2026-11-01 Epub Date: 2026-05-04 DOI: 10.1016/j.molmed.2026.04.004
Md Ibrahim, Md Shahadat Hossain, Lezanne Ooi, Md Mahmudul Hasan, Shandra Ahsan, Aliasger K Salem, Gary A Piazza, Xiaodong Feng, Fakhrul Ahsan
{"title":"Targeting the NAD<sup>+</sup>-PARP1-XRCC1 axis in ALS.","authors":"Md Ibrahim, Md Shahadat Hossain, Lezanne Ooi, Md Mahmudul Hasan, Shandra Ahsan, Aliasger K Salem, Gary A Piazza, Xiaodong Feng, Fakhrul Ahsan","doi":"10.1016/j.molmed.2026.04.004","DOIUrl":"10.1016/j.molmed.2026.04.004","url":null,"abstract":"<p><p>Amyotrophic lateral sclerosis (ALS) remains a fatal neurodegenerative disease with few effective therapies. Emerging evidence indicates that oxidative DNA damage, defective base excision and single-strand break repair, and progressive NAD<sup>+</sup> depletion contribute to motor neuron degeneration. The NAD<sup>+</sup>-PARP1-XRCC1 axis sits at the intersection of genome maintenance and metabolic control, linking DNA damage signaling to cellular bioenergetics. When dysregulated, this pathway may drive persistent PARP1 activation, failed repair, and energetic collapse. In this review, we integrate mechanistic and translational evidence supporting this axis as a therapeutic target in ALS. We propose a staged translational framework that prioritizes repurposable low-trapping PARP1 inhibitors combined with NAD<sup>+</sup> support, followed by central nervous system-directed RNA-lipid nanoparticle delivery of repair factors, with poly(ADP-ribose) and NAD<sup>+</sup> metabolites as pharmacodynamic biomarkers.</p>","PeriodicalId":23263,"journal":{"name":"Trends in molecular medicine","volume":" ","pages":"1100-1113"},"PeriodicalIF":18.1,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147843060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书